Mylan says it is approaching $1bn in total cumulative biosimilars sales, also disclosing during its second-quarter results call that its annual sales from biosimilars were now sitting at around $500m.
Describing the biosimilars business as “one of our key long-term growth opportunities,” Mylan president Rajiv Malik revealed that “this year our approximate